FDA Delays PPAR Development Pending Carcinogenicity Tests, Ligand Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is requiring sponsors of PPAR agents to conduct two-year rodent carcinogenicity studies prior to entering into clinical studies longer than six months in duration. Lilly/Ligand’s naveglitazar development will be postponed between 18 and 24 months.
You may also be interested in...
Lilly’s Research Focus Narrows From Five Therapeutic Areas To Four
Lilly is narrowing its research focus to four therapeutic areas, CEO Sidney Taurel said
Lilly’s Research Focus Narrows From Five Therapeutic Areas To Four
Lilly is narrowing its research focus to four therapeutic areas, CEO Sidney Taurel said
Bristol Expects FDA Advisory Committee Review Of Muraglitazar
Bristol-Myers Squibb expects FDA will hold an advisory committee meeting to discuss the application for its dual PPAR agonist muraglitazar